Product information and disease descriptionProduct description
Phase of product development
15 evidence topics · 9 sources
Summary: regulatory history and status
- Current status: under FDA review. Apnimed submitted a New Drug Application (NDA) for Oxnimbi (AD109) through the section 505(b)(2) pathway in April 2026; the FDA accepted it for review in July 2026 and assigned a PDUFA goal date of February 28, 2027. The 10-Q states that the review cycle is targeted at 10 months from the April 2026 submission. No launch date has been stated.
- Designations: Fast Track designation for the treatment of OSA in May 2022.
- Proprietary name: Oxnimbi is a proposed name. The prospectus states that the FDA conditionally approved it in May 2025, reconfirmed it in June 2026, and that it is pending approval of the NDA; the third quarter 2026 release states that it remains subject to final FDA review and may change.
- Combination product requirement: as a fixed-dose combination, the product generally requires the sponsor to demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.
- FDA questions: at the pre-NDA meeting, the FDA gave feedback on the “clinical meaningfulness of certain endpoint results”, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. Apnimed states that it responded in the NDA. The third quarter 2026 Form 10-Q states that the FDA, in its acceptance letter and later communications, has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas; its risk factors name the adequacy of stability data and the manufacturing process.
- Development completed: 13 phase 1, 2, and 3 trials, including two registrational phase 3 trials (LunAIRo in the United States and SynAIRgy in the United States and Canada).
- Earlier timing statements, now superseded: the May 2025 and July 2025 topline releases planned an NDA submission by early 2026; the March 2026 release expected submission in the second quarter of 2026; the April 2026 debt financing release expected it later that quarter; the May 2026 SynAIRgy publication release expected a PDUFA target action date in the first quarter of 2027, subject to FDA acceptance. The July 2026 acceptance, with a goal date of February 28, 2027, replaced these statements.
Regulatory status: Under review; NDA submitted April 2026 and accepted July 2026, with a PDUFA goal date of February 2027
Launch
No evidence found.